Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Expert Rev Vaccines. 2012 Dec;11(12):1405-13. doi: 10.1586/erv.12.126.

Abstract

A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Aluminum Compounds / administration & dosage
  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology*
  • Clinical Trials as Topic
  • Humans
  • Lipid A / administration & dosage
  • Membrane Glycoproteins / immunology*
  • Phosphates / administration & dosage
  • Protein Structure, Tertiary
  • SARS Virus / immunology*
  • SARS Virus / pathogenicity
  • Severe Acute Respiratory Syndrome / immunology
  • Severe Acute Respiratory Syndrome / prevention & control*
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Subunit / immunology
  • Vaccines, Synthetic / immunology
  • Viral Envelope Proteins / immunology*
  • Viral Vaccines / immunology*

Substances

  • Adjuvants, Immunologic
  • Aluminum Compounds
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antigens, Viral
  • Lipid A
  • MHV surface projection glycoprotein
  • Membrane Glycoproteins
  • Phosphates
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Vaccines
  • spike glycoprotein, SARS-CoV
  • aluminum phosphate